Vnitr Lek 2013, 59(3):160-164

What has the largest study in the history of diabetology brought us?

Z. Rušavý1,*, S. Lacigová1, M. Kvapil2
1 I. interní klinika Lékařské fakulty UK a FN Plzeň, přednosta prof. MUDr. Martin Matějovič, Ph.D.
2 Interní klinika 2. lékařské fakulty UK a FN Motol Praha, přednosta prof. MUDr. Milan Kvapil, CSc., MBA

The main objective of the ORIGIN study was an observation of the effects of treatment with insulin analogue, insulin glargine on cardiovascular complications in patients with severe atherosclerosis and early stages of well-compensated diabetes and prediabetes. The authors expected that a long-term reduction of glycaemia on an empty stomach will reduce the number of occurrences of cardiovascular complications. The study, which was conducted over a period of more than six years, showed neither a positive nor a negative effect of insulin treatment on cardiovascular complications. The second main objective of the study was the following: to compare the effect of the ω-3 fatty acid treatment versus placebo on the development of cardiovascular complications. However, no influence of n-3 fatty acids on the development of cardiovascular complications was found. The study investigated whether the insulin glargine treatment leads to an increased number of cancer occurrences. No correlation between cancer and the insulin glargine treatment was proven in this study. Long-term insulin treatment in the early stages of diabetes led to a minimal increase in weight through the course of six years (1.5kg) and to three times more hypoglycaemia occurrences compared to placebo. However, the number of hypoglycaemia occurrences was very small.

Conclusion:
The study has confirmed the safety of the insulin glargine treatment combined with metformin in the early stages of diabetes, without an increased number of atherosclerosis or cancer occurrences, and with minimal weight gain.

Keywords: diabetes mellitus; glargine; cardiovascular complications; prediabetes; ω-3 fatty acid treatment; hypoglycaemia

Received: December 22, 2012; Accepted: January 21, 2013; Published: March 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rušavý Z, Lacigová S, Kvapil M. What has the largest study in the history of diabetology brought us? Vnitr Lek. 2013;59(3):160-164.
Download citation

References

  1. Patel A. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 359: 2560-2572. Go to original source...
  2. Duckworth W, Abraira C, Moritz T et al. Intensive glucose control and complications in American veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139. Go to original source... Go to PubMed...
  3. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559. Go to original source... Go to PubMed...
  4. Charvat J, Michalova K, Chlumsky J et al. The significance of carotid artery plaques in the detection of coronary artery disease in asymptomatic type 2 diabetic patients. J Int Med Res 2006; 34: 13-20. Go to original source... Go to PubMed...
  5. The ORIGIN trial investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328. Go to original source... Go to PubMed...
  6. The ORIGIN trial investigators. N-3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. N Engl J Med 2012; 367: 309-318. Go to original source... Go to PubMed...
  7. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-2222. Go to original source... Go to PubMed...
  8. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412. Go to original source... Go to PubMed...
  9. Rhoads GG et al. Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following in 1753-itiation of neutral protamine Hagedorn insulin versus insulin glargin. Amer J Cardiol 2009; 16: 910-916. Go to original source... Go to PubMed...
  10. Weng J et al. Effect of intensive insulin therapy on beta cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371: 1760-1764. Go to original source... Go to PubMed...
  11. Retnakaran R, Zinman B. Short term intensified insulin treatment in type 2 diabetes: long term effects on beta cell function. Diab Obes Metabolism 2012; 14: (Suppl. 3): 161-166. Go to original source... Go to PubMed...
  12. Harrison LB, Adams-Huet B, Raskin P et al. Beta-cell function preservation after 3,5 years of intensive diabetes therapy. Diab Care 2012; 35: 1406-1412. Go to original source... Go to PubMed...
  13. Marchioli R, Barzi F, Bomba E et al. GISSI-Prevenzione Investigators: Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105: 1897-1903. Go to original source... Go to PubMed...
  14. Kromhout D, Giltay EJ, Geleijnse M for Alfa Omega Trial Group. N-3 Fatty Acids and Cardiovascular Events after Myocardial Infarction. N Engl J Med 2010; 363: 2015-2026. Go to original source... Go to PubMed...
  15. Filion KB, El Khoury F, Bielinski M et al. Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials. BMC Cardiovascular Disorders 2010; 10: 24. Go to original source... Go to PubMed...
  16. Inzucchi SE et al. Management of hyperglycemia in type 2 Diabetes: A Patient-Centred Approach. Diabetes Care Publish Ahead of Print online April 19, 2012. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.